Advances in the Treatment of Monoclonal Gammopaties: The Emerging Role of Targeted Therapy in Plasma Cell Dyscrasias

DSpace/Manakin Repository

Advances in the Treatment of Monoclonal Gammopaties: The Emerging Role of Targeted Therapy in Plasma Cell Dyscrasias

Show simple item record

dc.contributor.author Blotta, Simona
dc.contributor.author Malagola, Michele
dc.contributor.author Russo, Domenico
dc.contributor.author Roccaro, Aldo M.
dc.contributor.author Ghobrial, Irene
dc.contributor.author Treon, Steven P.
dc.contributor.author Anderson, Kenneth Carl
dc.date.accessioned 2010-12-08T20:12:07Z
dc.date.issued 2008
dc.identifier.citation Roccaro, Aldo M., Irene M. Ghobrial, Simona Blotta, Steven P. Treon, Michele Malagola, Kenneth C. Anderson, Paul G. Richardson, and Domenico Russo. 2008. Advances in the treatment of monoclonal gammopaties: The emerging role of targeted therapy in plasma cell dyscrasias. Biologics: Targets & Therapy 2(3): 419-431. en_US
dc.identifier.issn 1177-5475 en_US
dc.identifier.uri http://nrs.harvard.edu/urn-3:HUL.InstRepos:4621127
dc.description.abstract The paradigm for the treatment of monoclonal gammopaties has dramatically changed: therapeutic options in multiple myeloma (MM) have evolved from the introduction of melphalan and prednisone in the 1960s, high-dose chemotherapy and stem cell transplantation in the late 1980s and 1990s, to the rapid introduction of small novel molecules within the last seven years. Based on the understanding of the complex interaction of the MM cells with the bone marrow microenvironment and the signaling pathways that are dysregulated in this process, a number of novel therapeutic agents are now available. Specifically, three novel agents with a specific-targeted anti-MM activity, have been FDA-approved for the treatment of this disease, namely Bortezomib, thalidomide, and lenalidomide which are now all playing a key role in the treatment of MM. The success of targeted therapy in MM has since led to the development and investigation of more than 30 new compounds in this disease and in other plasma cell dyscrasias such as Waldenström’s macroglobulinemia and primary amyloidosis, both in the preclinical settings and as part of clinical trials. en_US
dc.language.iso en_US en_US
dc.publisher Dove Medical Press en_US
dc.relation.isversionof http://www.dovepress.com/biologics-targets--therapy-journal en_US
dc.relation.hasversion http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2721375/pdf/ en_US
dash.license LAA
dc.title Advances in the Treatment of Monoclonal Gammopaties: The Emerging Role of Targeted Therapy in Plasma Cell Dyscrasias en_US
dc.type Journal Article en_US
dc.description.version Version of Record en_US
dc.relation.journal Biologics : Targets & Therapy en_US
dash.depositing.author Roccaro, Aldo M.
dc.date.available 2010-12-08T20:12:07Z
dash.affiliation.other HMS^Medicine-Brigham and Women's Hospital en_US
dash.affiliation.other HMS^Medicine-Brigham and Women's Hospital en_US
dash.affiliation.other HMS^Medicine-Brigham and Women's Hospital en_US
dash.affiliation.other HMS^Medicine-Brigham and Women's Hospital en_US
dash.affiliation.other HMS^Medicine-Brigham and Women's Hospital en_US

Files in this item

Files Size Format View
2721375.pdf 644.4Kb PDF View/Open

This item appears in the following Collection(s)

Show simple item record

 
 

Search DASH


Advanced Search
 
 

Submitters